Chiu JWY - Search Results

1

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.

Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. Hurvitz SA, et al. Among authors: chiu jwy. Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. Lancet. 2023. PMID: 36495879 Free article. Clinical Trial.

2

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.

Iwata H, Masuda N, Kim SB, Inoue K, Rai Y, Fujita T, Chiu J, Ohtani S, Takahashi M, Miyaki T, Lu YS, Xu B, Yap YS, Bustam A, Yao B, Zhang B, Bryce R, Chan A. Iwata H, et al. Future Oncol. 2019 Jul;15(21):2489-2501. doi: 10.2217/fon-2019-0143. Epub 2019 May 29. Future Oncol. 2019. PMID: 31140297 Clinical Trial.

3

Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.

Dawood S, Chiu JW, Huang CS, Nag S, Sookprasert A, Yap YS, Md Yusof M. Dawood S, et al. Curr Med Res Opin. 2020 Aug;36(8):1363-1373. doi: 10.1080/03007995.2020.1783646. Epub 2020 Jul 2. Curr Med Res Opin. 2020. PMID: 32544344

4

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. Among authors: chiu jwy. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.

5

Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study.

Wong CY, Leung R, Kwok GW, Tsang J, Li B, Yau T, Chiu J. Wong CY, et al. Postgrad Med J. 2022 Sep 1;98(1163):666-669. doi: 10.1136/postgradmedj-2021-140319. Postgrad Med J. 2022. PMID: 37062975

6

Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.

Chiu JWY, Lee SC, Ho JC, Park YH, Chao TC, Kim SB, Lim E, Lin CH, Loi S, Low SY, Teo LLS, Yeo W, Dent R. Chiu JWY, et al. Drug Saf. 2023 Oct;46(10):927-949. doi: 10.1007/s40264-023-01328-x. Epub 2023 Aug 8. Drug Saf. 2023. PMID: 37552439 Free PMC article. Review.

7

Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial.

Chiu J, Su F, Joshi M, Masuda N, Ishikawa T, Aruga T, Zarate JP, Babbar N, Balbin OA, Yap YS. Chiu J, et al. BMC Med. 2023 Aug 15;21(1):306. doi: 10.1186/s12916-023-03017-z. BMC Med. 2023. PMID: 37580773 Free PMC article. Clinical Trial.

8

Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.

Wong H, Lau S, Leung R, Chiu J, Cheung P, Wong TT, Liang R, Epstein RJ, Yau T. Wong H, et al. Med Oncol. 2012 Sep;29(3):1536-42. doi: 10.1007/s12032-011-0082-y. Epub 2011 Oct 8. Med Oncol. 2012. PMID: 21983862

9

Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.

Wong H, Leung R, Kwong A, Chiu J, Liang R, Swanton C, Yau T. Wong H, et al. Oncologist. 2011;16(11):1535-46. doi: 10.1634/theoncologist.2011-0165. Epub 2011 Oct 21. Oncologist. 2011. PMID: 22020213 Free PMC article. Review.

10

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.

Kim SB, Do IG, Tsang J, Kim TY, Yap YS, Cornelio G, Gong G, Paik S, Lee S, Ng TY, Park S, Oh HS, Chiu J, Sohn J, Lee M, Choi YJ, Lee EM, Park KH, Nathaniel C, Ro J. Kim SB, et al. Cancer Res Treat. 2019 Oct;51(4):1527-1539. doi: 10.4143/crt.2018.598. Epub 2019 Jun 4. Cancer Res Treat. 2019. PMID: 31163957 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page